KRAS G12C inhibitors versus chemotherapy in second line and beyond in adults with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring the KRAS G12C mutation - PubMed
5 days ago
- #NSCLC
- #Chemotherapy
- #KRAS G12C
- Protocol for a Cochrane Review comparing KRAS G12C inhibitors versus chemotherapy in second-line treatment for advanced/metastatic NSCLC with KRAS G12C mutation.
- Objective: Assess benefits and harms of G12C-inhibitors vs. chemotherapy in adults with KRAS G12C-mutated NSCLC.
- Authors AN, KJ, FV, YH, BV, OA report no conflicts of interest.
- Author RG participated in advisory boards for Janssen Pharmaceuticals (payments to institution).
- Author LH reports extensive research funding, honoraria, advisory roles, and guideline committee involvement, mostly with payments to institution.
- Author WvG serves as an officer for NVALT and NCR, with site investigator roles in trials funded by Roche, Pfizer, Novartis, Novocure, and MSD.